rasagiline Side Effects
Also known as: Azilect
Analysis of 3,152 adverse event reports submitted to the FDA from 2007 to 2025.
Total Reports
3,152
Death-Related
358
11.4% of reports
Hospitalizations
971
30.8% of reports
Top Indication
Parkinson^S Disease
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 358 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 200 |
| HALLUCINATION | 36 |
| FALL | 32 |
| PARKINSON^S DISEASE | 30 |
| COMPLETED SUICIDE | 21 |
| PRODUCT DOSE OMISSION ISSUE | 19 |
| OFF LABEL USE | 18 |
| CONFUSIONAL STATE | 17 |
| DYSKINESIA | 15 |
| PNEUMONIA | 15 |
| DYSPHAGIA | 13 |
| URINARY TRACT INFECTION | 13 |
| ERECTILE DYSFUNCTION | 12 |
| DELUSION | 11 |
| CONDITION AGGRAVATED | 10 |
| ASTHENIA | 9 |
| DIARRHOEA | 9 |
| DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 9 |
| PRODUCT USE IN UNAPPROVED INDICATION | 9 |
| WEIGHT DECREASED | 9 |
Reactions in Hospitalization Reports
Top reactions in 971 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| FALL | 208 |
| DRUG INTERACTION | 101 |
| HALLUCINATION | 94 |
| DYSKINESIA | 92 |
| PARKINSON^S DISEASE | 75 |
| CONFUSIONAL STATE | 74 |
| SEROTONIN SYNDROME | 69 |
| GAIT DISTURBANCE | 65 |
| DIZZINESS | 59 |
| DYSPNOEA | 54 |
| CONDITION AGGRAVATED | 53 |
| URINARY TRACT INFECTION | 52 |
| DRUG INEFFECTIVE | 48 |
| ASTHENIA | 47 |
| OFF LABEL USE | 47 |
| CONSTIPATION | 45 |
| DELIRIUM | 44 |
| FATIGUE | 44 |
| MOBILITY DECREASED | 43 |
| TREMOR | 43 |
Nearby — Related Medications
What the FAERS Data Reveals About rasagiline Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 3,152 voluntary reports linked to rasagiline and its brand equivalents (Azilect), spanning 2007 through 2025. Of those, 358 (11.4%) listed death as an outcome and 971 (30.8%) involved hospitalization. The most common indication reported alongside adverse events was Parkinson^S Disease.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 38% were female and 62% male; age distribution skews toward 75+, with 748 reports in that bracket. The single most reported reaction is fall with 343 submissions, followed by hallucination and dyskinesia.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.